Norgine Danmark A/SAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Regnskabstal2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||||
| Likvide beholdninger | 3.584.000 | 2.215.000 | 20.408.000 | 1.351.000 | 28.436.000 | 838.000 | 11.647.000 | 4.845.000 | 529.000 |
| Omsætningsaktiver i alt | 62.512.000 | 67.422.000 | 68.420.000 | 112.925.000 | 117.777.000 | 112.745.000 | 141.737.000 | — | — |
| Anlægsaktiver i alt | 506.000 | 345.000 | 163.000 | 1.309.000 | 1.038.000 | 813.000 | 579.000 | 614.000 | 1.030.000 |
| Aktiver i alt | 63.018.000 | 67.767.000 | 68.583.000 | 114.234.000 | 118.815.000 | 113.558.000 | 142.316.000 | 175.354.000 | 191.697.000 |
| Balance — passiver | |||||||||
| Kortfristede gældsforpligtelser | 8.896.000 | 13.323.000 | 12.139.000 | 52.218.000 | 50.193.000 | 45.139.000 | 68.748.000 | 91.429.000 | 102.743.000 |
| Langfristede gældsforpligtelser | — | — | — | — | — | — | — | — | — |
| Gældsforpligtelser i alt | 8.896.000 | 13.323.000 | 12.139.000 | 52.218.000 | 50.193.000 | 45.139.000 | 68.748.000 | 91.429.000 | 102.743.000 |
| Selskabskapital | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 | 500.000 |
| Overført resultat | 53.622.000 | 53.944.000 | 55.944.000 | 61.516.000 | 68.122.000 | 67.919.000 | 73.068.000 | 83.425.000 | 88.454.000 |
| Årets resultat | 770.000 | 322.000 | 2.000.000 | 5.572.000 | 6.606.000 | -203.000 | 5.149.000 | 10.357.000 | 4.691.000 |
| Egenkapital i alt | 54.122.000 | 54.444.000 | 56.444.000 | 62.016.000 | 68.622.000 | 68.419.000 | 73.568.000 | 83.925.000 | 88.954.000 |
| Resultatopgørelse | |||||||||
| Bruttofortjeneste | 16.668.000 | 17.598.000 | 19.904.000 | 26.944.000 | 25.479.000 | 22.947.000 | 28.269.000 | 28.771.000 | 26.083.000 |
| Resultat af primær drift | 2.160.000 | 674.000 | 3.380.000 | 9.661.000 | 8.127.000 | 4.406.000 | 9.936.000 | 12.432.000 | 6.633.000 |
| EBITDA | 2.478.000 | 972.000 | 3.616.000 | 9.857.000 | 8.497.000 | 4.869.000 | 10.346.000 | 12.740.000 | 6.953.000 |
| Resultat før skat | 1.000.000 | 442.000 | 2.601.000 | 7.192.000 | 8.635.000 | -326.000 | 6.443.000 | 13.522.000 | 6.134.000 |
| Årets resultat | 770.000 | 322.000 | 2.000.000 | 5.572.000 | 6.606.000 | -203.000 | 5.149.000 | 10.357.000 | 4.691.000 |
| Personaleomkostninger | 14.190.000 | 16.626.000 | 16.288.000 | 17.087.000 | 16.982.000 | 18.078.000 | 17.923.000 | 16.031.000 | 19.130.000 |
| Af- og nedskrivninger | 318.000 | 298.000 | 236.000 | 196.000 | 370.000 | 463.000 | 410.000 | 308.000 | 320.000 |
| Andre nøgletal | |||||||||
| Ansatte | 16 | 17 | 18 | 18 | 19 | 17 | 16 | 14 | 17 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Business review The principal activities of the Company comprise sale and marketing of pharmaceutical products and related activities.
Financial review The income statement for 2025 shows a profit of DKK 4,691 thousand against a profit of DKK 10,357 thousand last year, and the balance sheet at 31 December 2025 shows equity of DKK 88,954 thousand. In the annual report for 2024, the Directors expected the Profit before net interest and tax for 2025 to be at a consistent level to 2024. Net profit for 2025 decreased 55%. The distribution costs increased by 16% in 2025 compared to 2024, with increased costs to Movianto Nordics ApS. Other impacting areas to the result in the year were increased salary costs and a reduction in intercompany interest. Financial risks and use of financial instruments As well as for the Norgine Group, the entity’s operations expose it to a variety of risks that can be broadly grouped into the following categories: Strategy, Operational Activities, Financial Position/Reporting and Laws and Regulations. The Norgine Group’s and thus Norgine Denmark A/S’s growth and overall business success is dependent in part on the Group’s ability to introduce new products and further develop existing products that benefit patients and offer real value to healthcare professionals. Clinical development and regulatory approval of a pharmaceutical or medical device product is a very intensive and costly process and is subject to a high risk of failure in every phase of development. In some cases regulatory approval might not be received or might be restricted to certain geographical regions or indications,
Uddrag af ledelsesberetningen i den seneste årsrapport.